For TIGIT target, the ongoing/upcoming phase III clinical studies on advanced first-line NSCLC treatment in China include the following: MK-7684A-003 trial (PD-L1 ≥ 1%, MK-7684 + Pembrolizumab, NCT04738487), AdvanTIG-302 trial (PD-L1 ≥ 50%, BGB-A1217 + Teicilizumab, NCT04746924), and SKYSCRAPER-01 trial (high PD-L1 expression, Tiragolumab + Atenibizumab, NCT04294810). Here, CD274 is linked to non-small cell lung carcinoma.